Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China

Aims: This study aimed to evaluate the cost-effectiveness of lenvatinib plus pembrolizumab (LP) vs. chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China. Methods: A lifetime of partitioned survival Markov was used to evaluate the overall l...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhiwei, Yang, Liu, Xu, Siqi, Zhu, Huide, Cai, Hongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561308/
https://www.ncbi.nlm.nih.gov/pubmed/36249813
http://dx.doi.org/10.3389/fphar.2022.944931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561308/
https://www.ncbi.nlm.nih.gov/pubmed/36249813
http://dx.doi.org/10.3389/fphar.2022.944931

Ejemplares similares